Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme

Glioblastoma multiforme (GBM) is one of the deadliest brain tumors with an unfavorable prognosis and overall survival of approximately 20 months following diagnosis. The current treatment for GBM includes surgical resections and chemo‐ and radiotherapeutic modalities, which are not effective. CAR‐T...

Descripción completa

Detalles Bibliográficos
Autores principales: Marei, Hany E., Althani, Asmaa, Afifi, Nahla, Hasan, Anwarul, Caceci, Thomas, Pozzoli, Giacomo, Cenciarelli, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335808/
https://www.ncbi.nlm.nih.gov/pubmed/34145792
http://dx.doi.org/10.1002/cam4.4064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335808/
https://www.ncbi.nlm.nih.gov/pubmed/34145792
http://dx.doi.org/10.1002/cam4.4064

Ejemplares similares